Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
As at 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2022-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Name of reporting entity or other means of identification | — |
ABIONYX Pharma
|
— |
| Domicile of entity | — |
France
|
— |
| Legal form of entity | — |
société anonyme
|
— |
| Address of entity's registered office | — |
33-43 avenue Georges Pompidou – Bâtiment D – 31130 Balma
|
— |
| Description of nature of entity's operations and principal activities | — |
ABIONYX Pharma est une société biotech de nouvelle génération qui entend contribuer à la santé grâce à des thérapies innovantes dans des indications sans traitement efficace ou existant, même les plus rares.
|
— |
| Statement of IFRS compliance [text block] | — |
ii.
|
— |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current inventories |
221,000
EUR
|
— |
147,000
EUR
|
| Current trade payables |
1 439
EUR
|
— |
1 853
EUR
|
| Disclosure of material accounting policy information [text block] | — |
i.
|
— |